PARP inhibitors

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
Clovis looks to expand label for PARP inhibitor
Biopharma Dive
Wed, 10/11/17 - 10:57 pm
Clovis Oncology
PARP inhibitors
Rubraca
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
A Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
Forbes
Mon, 09/11/17 - 09:16 am
pancreatic cancer
PARP inhibitors
Clovis Oncology
Rubraca
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Fierce Pharma
Wed, 08/16/17 - 10:05 am
Tesaro
Zejula
PARP inhibitors
earnings
Cancer-fighting PARP drugs from AstraZeneca, Clovis and Tesaro largely overpriced, watchdog says
Fierce Pharma
Thu, 07/13/17 - 09:33 pm
PARP inhibitors
AstraZeneca
Clovis Oncology
Tesaro
drug pricing
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
Fri, 07/7/17 - 10:18 am
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Is Clovis Oncology A Takeover Candidate?
Seeking Alpha
Mon, 06/26/17 - 04:54 pm
Clovis Oncology
M&A
rucaparib
PARP inhibitors
Can AstraZeneca Keep Up As Clovis, Tesaro Unveil Blockbuster Drugs?
Investors Business Daily
Mon, 06/19/17 - 07:16 am
AstraZeneca
Clovis
Tesaro
PARP inhibitors
Tesaro's PARP inhibitor approved in ovarian cancer
BioPharma Dive
Mon, 03/27/17 - 10:38 pm
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AZ gears up for FDA filing as PARP inhibitor Lynparza wins big in ovarian cancer trial
Fierce Pharma
Tue, 03/14/17 - 04:43 pm
AstraZeneca
PARP inhibitors
Lynparza
FDA
ovarian cancer
clinical trials
Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug
TheStreet.com
Mon, 12/19/16 - 11:51 am
Clovis Oncology
FDA
PARP inhibitors
rucaparib
ovarian cancer
Rubraca
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
Wed, 12/7/16 - 07:45 pm
AbbVie
breast cancer
veliparib
PARP inhibitors
BRCA-mutant breast cancer
Gilead Sciences, Inc. Can Fancy TESARO Inc for Acquisition
Bidness, ETC
Tue, 09/13/16 - 11:38 am
Gilead Sciences
PARP inhibitors
Tesaro
M&A
niraparib
Buyout target Medivation says cancer drug could be "best in class"
Yahoo/Reuters
Wed, 07/6/16 - 09:52 pm
Medivation
talazoparib
PARP inhibitors
Sanofi
M&A
An Overnight Double! Could These Drugmakers Be Next?
Motley Fool
Sat, 07/2/16 - 12:36 pm
Tesaro
ovarian cancer
PARP inhibitors
niraparib
AstraZeneca
Lynparza
Medivation
AbbVie
Clovis Oncology
Medivation: It’s Not Just M&A
Barron's
Mon, 04/18/16 - 10:15 am
Medivation
M&A
AstraZenca
Sanofi
Gilead Sciences
talazoparib
PARP inhibitors
Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?
Bioworld
Sat, 02/6/10 - 12:26 pm
Biomarin
PARP inhibitors
Sanofi-Aventis to Buy Cancer Drug Firm BiPar
TheStreet.com
Wed, 04/15/09 - 07:30 am
Sanofi
cancer
Bi-Par
buyouts
PARP inhibitors

Pages